Breast cancer indication for bevacizumab

Name: Relias Media
Price range: $

January 2, 2015

Breast cancer indication for bevacizumab

The Oncologic Drugs Advisory committee of the FDA has recommended removing the indication for breast cancer treatment for bevacizumab (Avastin^®). The 12-1 vote was made after data were presented that the drug provided no survival benefit when used in combination with docetaxel, while contributing significant adverse effects. Bevacizumab, a humanized monoclonal antibody, which blocks new blood vessel formation (angiogenesis inhibitor), also carries indications for treatment of colon, lung, kidney, and brain cancers.

Post Date: January 2, 2015

Table of Contents

Financial Disclosure: None of the authors or planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients

Subscription Publication

Books & Study Guides

Group & Site Licenses

State CME/CE Requirements